Modern glucose-lowering drugs SGLT2 inhibitors and GLP-1 agonists in the prevention of cardiovascular disease and dementia in patients with diabetes and metabolic disorders
A clinical pharmacological analysis of current data is presented, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorder...